Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Samsung Biologics has announced an all-cash public tender offer to acquire PolyPeptide Group AG, valuing the peptide-focused contract development and manufacturing organization at approximately CHF 1.46 billion.
read more
eXmoor Pharma and Evox Therapeutics have completed a technology transfer program for Evox’s exosome-enabled gene editing platform, including its MSH3-targeted program for Huntington’s disease, at eXmoor’s Bristol, UK facility.
read more
Phanes Therapeutics has expanded its clinical trial collaboration and supply agreement with Merck to evaluate spevatamig in combination with KEYTRUDA (pembrolizumab) and chemotherapy as a first-line treatment for biliary tract cancer (BTC).
read more
Lonza and Engitix have entered a licensing agreement aimed at advancing a new generation of antibody-drug conjugates (ADCs) that target the extracellular matrix (ECM) to treat chronic diseases. The deal combines Lonza’s clinically validated ADC ...
read more
Redwire Corporation has opened a new 30,000 square foot, state-of-the-art research and microgravity payload development facility in Georgetown, Indiana, designed to accelerate space-enabled R&D and manufacturing with a focus on next-generation drug ...
read more
Clinigen has appointed Greg Skalicky as Group Chief Executive Officer, effective July 20, 2026, succeeding Dr. Varun Sethi, who has served as Acting CEO since September 2025.
read more
Restore Vision and Forge Biologics, a manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, announced a development and manufacturing partner-ship to support RV-001, Restore Vision’s investigational GPCR-based optogenetic AAV ...
read more
The selection of Thermo Fisher represents an important Chemistry, Manufacturing and Controls (“CMC”) milestone for the Kapiglucagon program and is expected to support the next stages of pharmaceutical development and IND-enabling preparation.
read more
Wheeler Bio announced the appointment of Rajesh Beri, Ph.D., as Chief Development Officer.
read more
Bora Pharmaceuticals and Onconic Therapeutics have signed a manufacturing agreement to support the U.S. clinical development of JAQBO tablets, a potassium-competitive acid blocker being studied for gastroesophageal reflux disease.
read more
CluePoints has appointed Martin (Marty) Magazzolo as its new Chief Commercial Officer (CCO). Marty will lead CluePoints' global commercial organization, including sales, marketing, account management, and commercial operations, as the company ...
read more
Pace® Life Sciences announced the successful completion of an FDA inspection of its Small Molecule Center of Excellence in Research Triangle Park, North Carolina.
read more
Novogene Europe announced that it has expanded its single-cell RNA sequencing capability at its Cambridge Omics Centre. This expansion brings single-cell sequencing workflows built around the 10x Genomics Chromium platform closer to academic, biotech...
read more
ICON has announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle, expanding the company’s digital innovation and AI strategy through its secure agentic platform, Orbis.
read more
Harbour BioMed and China National Pharmaceutical Group announced a strategic collaboration to establish a joint innovation R&D consortium focused on advancing next-generation biologic therapies.
read more